C12orf65

Across TCGA pan-cancer cohorts, C12orf65 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of C12orf65’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where C12orf65 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C12orf65 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where C12orf65 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C12orf65 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.702	<.001	9	view →
LSCC	Female	II,III,IV	+0.565	<.001	8	view →
CCRCC	All	All	−0.303	<.001	5	view →
HNSC	Male	All	−0.273	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

C12orf65–LUAD

Open the LUAD breakdown →